RT Journal Article
SR Electronic
T1 Target Product Profiles for a Micronutrient Assessment Tool and Associated Blood Collection Device for Use in Population-Based Surveys: An Expert Consensus
JF medRxiv
FD Cold Spring Harbor Laboratory Press
SP 2021.05.13.21257124
DO 10.1101/2021.05.13.21257124
A1 Smith, Emily R.
A1 Lee, Joanne
A1 Allen, Lindsay H.
A1 Boyle, David S.
A1 Brindle, Eleanor
A1 Craft, Neal E.
A1 Dalmiya, Nita
A1 Erhardt, Juergen
A1 Garrett, Dean
A1 Jefferds, Maria Elena
A1 Kavishe, Festo
A1 Killilea, David W.
A1 Kung’u, Jaqueline K.
A1 Kurpad, Anura
A1 Loechl, Cornelia U.
A1 Moore, Sophie E.
A1 Namaste, Sorrel ML
A1 Pfeiffer, Christine M.
A1 Rohner, Fabian
A1 Schulze, Kerry
A1 Shaheen, Nazma
A1 Soofi, Sajid
A1 Winichagoon, Pattanee
A1 Thomas, Bethanie
A1 Osendarp, Saskia
A1 Rawat, Rahul
YR 2021
UL http://medrxiv.org/content/early/2021/05/18/2021.05.13.21257124.abstract
AB Micronutrient deficiencies are a significant public health problem affecting a large portion of the world’s population. Disproportionately affected populations—infants, young children, adolescents and women of reproductive age including pregnant women — are especially susceptible to the health consequences of insufficient micronutrient intakes. However, assessment of micronutrient deficiencies is not routinely included in population health surveys. This nutrition data gap hampers policy, program, and promotion efforts to prevent and treat micronutrient deficiencies. To address one of the barriers to micronutrient assessment, an expert group created a consensus of a target product profile (TPP) for a micronutrient assessment tool and associated blood collection device for use in population surveys. Experts in laboratory medicine, micronutrient assessment, population-based surveys, and product development reviewed proposed TPP standards and collaboratively established minimum and optimal characteristics. These experts defined the target population as infants and children from 6-59 months, adolescents and women of reproductive age 12-49 years including pregnant women. At minimum, the assessment tool should be a multiplex ELISA formatted for >1 analyte that uses a serum or plasma sample prepared from venous blood obtained by a phlebotomist with a 2-week training. Given the use case was specific for population surveys, experts agreed the minimum tool could be semi-quantitative, with analytical specificity of 99%. The TPP also considers the variable field environments for testing (e.g. storage conditions and time to results). The consensus TPP developed can be used to guide selection of existing technologies into population-based surveys, as well as future investment in product development. Partnerships focused on research and development—including industry, public sector, nonprofit, and academic institutions—can help advance the field and fill the micronutrient data gap.Competing Interest StatementAll authors have completed the ICMJE uniform disclosure form at www.icmje.org/coi_disclosure.pdf and declare: Ms. Thomas and Ms. Lee report personal fees from Bill & Melinda Gates Foundation, during the conduct of the study and personal fees from Bill & Melinda Gates Foundation, outside the submitted work; all authors declare no other relationships or activities that could appear to have influenced the submitted work.Funding StatementThe June 2019 convening was paid for by the Bill & Melinda Gates Foundation (https://www.gatesfoundation.org/). Experts and their institutions or grants paid for their own travel and lodging. Partial support (EB) came from a Eunice Kennedy Shriver National Institute of Child Health and Human Development research infrastructure grant (https://www.nih.gov/about-nih/what-we-do/nih-almanac/eunice-kennedy-shriver-national-institute-child-health-human-development-nichd), P2C HD042828, to the Center for Studies in Demography & Ecology at the University of Washington. Partial support for SN came from a grant to The DHS Program from the United States Agency for International Development (USAID) and the Bill & Melinda Gates Foundation (#720-OAA-18C-00083). Sponsors or funders played a role: ES, RR worked for the Bill & Melinda Gates Foundation at the time of project and contributed to the conceptualization, implementation, analysis, and drafting of the paper.Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:This is not human subjects research.All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesAll data is included in the manuscript and supplementary files.